CN104524275A - Chinese medicinal tablet for promoting recovery of patients from operation for bladder cancer preparation method thereof - Google Patents
Chinese medicinal tablet for promoting recovery of patients from operation for bladder cancer preparation method thereof Download PDFInfo
- Publication number
- CN104524275A CN104524275A CN201410788961.3A CN201410788961A CN104524275A CN 104524275 A CN104524275 A CN 104524275A CN 201410788961 A CN201410788961 A CN 201410788961A CN 104524275 A CN104524275 A CN 104524275A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- chinese medicinal
- medicinal tablet
- bladder cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 title claims abstract description 36
- 230000001737 promoting effect Effects 0.000 title claims abstract description 29
- 238000011084 recovery Methods 0.000 title claims abstract description 27
- 206010005003 Bladder cancer Diseases 0.000 title claims abstract description 25
- 201000005112 urinary bladder cancer Diseases 0.000 title claims abstract description 25
- 238000002360 preparation method Methods 0.000 title claims abstract description 7
- 239000000454 talc Substances 0.000 claims abstract description 14
- 229910052623 talc Inorganic materials 0.000 claims abstract description 14
- 239000002994 raw material Substances 0.000 claims abstract description 4
- 239000003814 drug Substances 0.000 claims description 42
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 30
- 210000001320 hippocampus Anatomy 0.000 claims description 30
- 239000000843 powder Substances 0.000 claims description 30
- 241000371997 Eriocheir sinensis Species 0.000 claims description 28
- 229940079593 drug Drugs 0.000 claims description 27
- 230000002980 postoperative effect Effects 0.000 claims description 27
- 239000010231 banlangen Substances 0.000 claims description 14
- 210000000582 semen Anatomy 0.000 claims description 14
- 239000009636 Huang Qi Substances 0.000 claims description 13
- 235000012222 talc Nutrition 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 239000004615 ingredient Substances 0.000 claims description 8
- 239000011230 binding agent Substances 0.000 claims description 7
- 239000000314 lubricant Substances 0.000 claims description 7
- 229920002472 Starch Polymers 0.000 claims description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 6
- 239000008107 starch Substances 0.000 claims description 6
- 235000019698 starch Nutrition 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 239000000706 filtrate Substances 0.000 claims description 5
- 239000012467 final product Substances 0.000 claims description 5
- 239000008187 granular material Substances 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 238000003756 stirring Methods 0.000 claims description 5
- 235000010443 alginic acid Nutrition 0.000 claims description 4
- 229920000615 alginic acid Polymers 0.000 claims description 4
- 229920001282 polysaccharide Polymers 0.000 claims description 4
- 239000005017 polysaccharide Substances 0.000 claims description 4
- 150000004804 polysaccharides Chemical class 0.000 claims description 4
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 3
- 244000068988 Glycine max Species 0.000 claims description 3
- 235000010469 Glycine max Nutrition 0.000 claims description 3
- 239000005913 Maltodextrin Substances 0.000 claims description 3
- 229920002774 Maltodextrin Polymers 0.000 claims description 3
- 229910000503 Na-aluminosilicate Inorganic materials 0.000 claims description 3
- 239000002202 Polyethylene glycol Substances 0.000 claims description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 3
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 claims description 3
- 235000013539 calcium stearate Nutrition 0.000 claims description 3
- 239000008116 calcium stearate Substances 0.000 claims description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 3
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 3
- 229940105329 carboxymethylcellulose Drugs 0.000 claims description 3
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 3
- 235000019359 magnesium stearate Nutrition 0.000 claims description 3
- 229940035034 maltodextrin Drugs 0.000 claims description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- 239000000741 silica gel Substances 0.000 claims description 3
- 229910002027 silica gel Inorganic materials 0.000 claims description 3
- 239000000429 sodium aluminium silicate Substances 0.000 claims description 3
- 235000012217 sodium aluminium silicate Nutrition 0.000 claims description 3
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 claims description 3
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 2
- 239000004375 Dextrin Substances 0.000 claims description 2
- 229920001353 Dextrin Polymers 0.000 claims description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- 229940072056 alginate Drugs 0.000 claims description 2
- 239000000783 alginic acid Substances 0.000 claims description 2
- 229960001126 alginic acid Drugs 0.000 claims description 2
- 150000004781 alginic acids Chemical class 0.000 claims description 2
- 235000019425 dextrin Nutrition 0.000 claims description 2
- 239000008172 hydrogenated vegetable oil Substances 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- 229960004793 sucrose Drugs 0.000 claims description 2
- 239000000230 xanthan gum Substances 0.000 claims description 2
- 229920001285 xanthan gum Polymers 0.000 claims description 2
- 235000010493 xanthan gum Nutrition 0.000 claims description 2
- 229940082509 xanthan gum Drugs 0.000 claims description 2
- 239000008280 blood Substances 0.000 abstract description 22
- 210000004369 blood Anatomy 0.000 abstract description 22
- 210000000952 spleen Anatomy 0.000 abstract description 13
- 208000019206 urinary tract infection Diseases 0.000 abstract description 13
- 208000004880 Polyuria Diseases 0.000 abstract description 10
- 230000035619 diuresis Effects 0.000 abstract description 10
- 230000017531 blood circulation Effects 0.000 abstract description 9
- 210000003734 kidney Anatomy 0.000 abstract description 7
- 241000193830 Bacillus <bacterium> Species 0.000 abstract description 6
- 230000010412 perfusion Effects 0.000 abstract description 6
- 238000010926 purge Methods 0.000 abstract description 6
- 230000002262 irrigation Effects 0.000 abstract description 5
- 238000003973 irrigation Methods 0.000 abstract description 5
- 241000213006 Angelica dahurica Species 0.000 abstract description 3
- 230000036039 immunity Effects 0.000 abstract description 3
- 238000005728 strengthening Methods 0.000 abstract description 3
- 230000001939 inductive effect Effects 0.000 abstract description 2
- 230000002401 inhibitory effect Effects 0.000 abstract description 2
- 229960005486 vaccine Drugs 0.000 abstract description 2
- 241000405414 Rehmannia Species 0.000 abstract 2
- 230000003014 reinforcing effect Effects 0.000 abstract 2
- 241000722953 Akebia Species 0.000 abstract 1
- 241001061264 Astragalus Species 0.000 abstract 1
- 235000010110 Astragalus glycyphyllos Nutrition 0.000 abstract 1
- 244000025254 Cannabis sativa Species 0.000 abstract 1
- 244000192528 Chrysanthemum parthenium Species 0.000 abstract 1
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 abstract 1
- 241000576429 Forsythia suspensa Species 0.000 abstract 1
- 235000018142 Hedysarum alpinum var americanum Nutrition 0.000 abstract 1
- 240000006461 Hedysarum alpinum var. americanum Species 0.000 abstract 1
- 241001598107 Imperata Species 0.000 abstract 1
- 241000207783 Ipomoea Species 0.000 abstract 1
- 235000000802 Leonurus cardiaca ssp. villosus Nutrition 0.000 abstract 1
- 244000241838 Lycium barbarum Species 0.000 abstract 1
- 235000015459 Lycium barbarum Nutrition 0.000 abstract 1
- 235000015468 Lycium chinense Nutrition 0.000 abstract 1
- 240000005373 Panax quinquefolius Species 0.000 abstract 1
- 235000003140 Panax quinquefolius Nutrition 0.000 abstract 1
- 241000972673 Phellodendron amurense Species 0.000 abstract 1
- 241000756042 Polygonatum Species 0.000 abstract 1
- 235000008737 Polygonatum biflorum Nutrition 0.000 abstract 1
- 244000292697 Polygonum aviculare Species 0.000 abstract 1
- 240000004534 Scutellaria baicalensis Species 0.000 abstract 1
- 235000017089 Scutellaria baicalensis Nutrition 0.000 abstract 1
- 241001247203 Syngnathidae Species 0.000 abstract 1
- 239000000853 adhesive Substances 0.000 abstract 1
- 230000001070 adhesive effect Effects 0.000 abstract 1
- 235000006533 astragalus Nutrition 0.000 abstract 1
- 239000002775 capsule Substances 0.000 abstract 1
- 235000013399 edible fruits Nutrition 0.000 abstract 1
- 239000003053 toxin Substances 0.000 abstract 1
- 231100000765 toxin Toxicity 0.000 abstract 1
- 108700012359 toxins Proteins 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 21
- 208000024891 symptom Diseases 0.000 description 21
- 238000002560 therapeutic procedure Methods 0.000 description 15
- 238000000034 method Methods 0.000 description 13
- 230000027939 micturition Effects 0.000 description 13
- 230000002265 prevention Effects 0.000 description 13
- 210000003932 urinary bladder Anatomy 0.000 description 13
- 208000002193 Pain Diseases 0.000 description 8
- 230000005784 autoimmunity Effects 0.000 description 8
- 208000006750 hematuria Diseases 0.000 description 8
- 238000002271 resection Methods 0.000 description 8
- 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 description 7
- 239000002671 adjuvant Substances 0.000 description 6
- 238000007086 side reaction Methods 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 5
- 230000001717 pathogenic effect Effects 0.000 description 5
- 231100000614 poison Toxicity 0.000 description 5
- 239000003440 toxic substance Substances 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 208000030208 low-grade fever Diseases 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 206010011224 Cough Diseases 0.000 description 3
- 206010019233 Headaches Diseases 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000003750 conditioning effect Effects 0.000 description 3
- 206010061428 decreased appetite Diseases 0.000 description 3
- 208000001848 dysentery Diseases 0.000 description 3
- 206010013990 dysuria Diseases 0.000 description 3
- 231100000869 headache Toxicity 0.000 description 3
- 230000002045 lasting effect Effects 0.000 description 3
- 230000002632 myometrial effect Effects 0.000 description 3
- 230000036565 night sweats Effects 0.000 description 3
- 206010029410 night sweats Diseases 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 206010063057 Cystitis noninfective Diseases 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 241000531795 Salmonella enterica subsp. enterica serovar Paratyphi A Species 0.000 description 2
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 206010043458 Thirst Diseases 0.000 description 2
- 241000607626 Vibrio cholerae Species 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 230000000118 anti-neoplastic effect Effects 0.000 description 2
- 206010003549 asthenia Diseases 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 201000003139 chronic cystitis Diseases 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 201000003146 cystitis Diseases 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 208000021760 high fever Diseases 0.000 description 2
- 201000001881 impotence Diseases 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000005906 menstruation Effects 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 230000003387 muscular Effects 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 230000001047 pyretic effect Effects 0.000 description 2
- 208000013223 septicemia Diseases 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 230000001502 supplementing effect Effects 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000035922 thirst Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 208000010445 Chilblains Diseases 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 208000008967 Enuresis Diseases 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 201000000297 Erysipelas Diseases 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 241001467552 Mycobacterium bovis BCG Species 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 206010028817 Nausea and vomiting symptoms Diseases 0.000 description 1
- 206010030302 Oliguria Diseases 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000005946 Xerostomia Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003471 anti-radiation Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 238000005429 filling process Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000002229 urogenital system Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/12—Magnesium silicate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/60—Fish, e.g. seahorses; Fish eggs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/612—Crustaceans, e.g. crabs, lobsters, shrimps, krill or crayfish; Barnacles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/19—Acanthaceae (Acanthus family)
- A61K36/195—Strobilanthes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
- A61K36/315—Isatis, e.g. Dyer's woad
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/39—Convolvulaceae (Morning-glory family), e.g. bindweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/533—Leonurus (motherwort)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
- A61K36/634—Forsythia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/756—Phellodendron, e.g. corktree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8969—Polygonatum (Solomon's seal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Marine Sciences & Fisheries (AREA)
- Insects & Arthropods (AREA)
- Inorganic Chemistry (AREA)
- Neurosurgery (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a Chinese medicinal tablet for promoting the recovery of patients from operation for bladder cancer and a preparation method thereof. The Chinese medicinal tablet is prepared from the following effective components (raw materials): American ginseng, manyflower solomonseal rhizomes, Chinese angelica, motherwort herb, sea horses, barbary wolfberry fruits, milkvetch roots, crab shells, fried liquorice roots, akebia stems, common knotgrass herb, Chinese corktree barks, weeping forsythia capsule, prepared rhizome of adhesive rehmannia, dried rehmannia roots, dahurian angelica roots, talc, indigowoad roots, lalang grass rhizomes, baikal skullcap eoots and pharbitis seeds. The Chinese medicinal tablet disclosed by the invention is used for preventing and treating complications caused by bladder irrigation after operation and improving the immunity of patients so as to promote the recovery of patients from operation for bladder cancer. The Chinese medicinal tablet has the efficacies of reinforcing the vital essence, strengthening the primordial qi, tonifying the spleen, nourishing yin, reinforcing the kidney, nourishing blood, purging intense heat, removing toxins, clearing heat, inducing diuresis, promoting blood circulation, removing blood stasis, tonifying Qi and raising yang, can be used for preventing and treating complications and urinary tract infections caused by perfusion of bacillus falmette guerin vaccines, improving the immunity and relieving the suffering of patients, promoting the recovery of patients from operation and inhibiting the recurrence of bladder cancer.
Description
Technical field
The present invention relates to and a kind ofly promote Chinese medicinal tablet of bladder cancer post-operative recovery and preparation method thereof, belong to technical field of traditional Chinese medicine preparation.
Background technology
Bladder cancer refers to the malignant tumor deriving from wall of urinary bladder epithelial tissue and stroma, is the modal malignant tumor of urinary system, accounts for first of China's Genitourinary system sickness rate.Surgical operation is the major way for the treatment of bladder cancer at present.Wherein, the first-selected underwent transurethral resection of bladder tumor of non-Myometrial involvement tumor of bladder is treated.Adopt the operation of this Wicresoft, body surface does not have the edge of a knife, and post-operative recovery is very fast.Underwent transurethral resection of bladder tumor need coordinate with bladder instillation to treat after surgery.Urinary tract infection to be caused because of misoperation in filling process to cause complication, also possiblely to lead to complications because of drug effect, wherein, mostly the complication that drug effect causes is to be caused by bacillus calmette-guerin vaccine.These complication, once occur often to upset the set therapeutic scheme of patient, affect patient body greatly healthy, extend the time of post-operative recovery.
Bacillus calmette-guerin vaccine is the immunization therapy dabbling drug that treatment tumor of bladder is commonly used.Can be adsorbed the reaction and mediated immunity response causes inflammation by mucous membrane of urinary bladder after Intravesical BCG bladder, this immunoreation can destroy tumor cell and prevent its recurrence and progress.Bacillus calmette-guerin vaccine is the most effective medicine of the non-Myometrial involvement bladder cancer of current accepted treatment.Be regarded as the most effective treatment means for the treatment of cancer in situ.Although Intravesical BCG Be very effective, its perfusion therapy side effect is very important equally.The side effect main manifestations that Intravesical BCG causes is local side reaction and whole body side reaction.The symptom main manifestations of local side reaction is urine urgency-frequency dysurea, and serious also there will be hematuria symptom.The origin cause of formation of whole body side reaction is because bacillus calmette-guerin vaccine belongs to attenuated live vaccine, and wherein still activated tubercule bacillus directly by the absorption of mucous membrane of urinary bladder or enter circulation by the open blood vessel of surgical wound surface, can cause the appearance of systemic side effect.A small amount of bacillus calmette-guerin vaccine absorbs, and can show as the tubercle bacillus affection symptom that low grade fever, night sweat, muscular soreness etc. are slight, with irritation sign of bladder, as activated tubercule bacillus is absorbed in a large number through open vascular bed, seriously also can cause Tuberculous septicemia.Except drug-induced complication,
Summary of the invention
The object of the invention is the complication of the treatment of the Intravesical BCG after prevention and therapy underwent transurethral resection of bladder tumor, and perfusion operates the urinary tract infection caused, promote bladder cancer patients post-operative recovery, alleviate patient suffering.Strengthen patient's autoimmunity two aspect from for disease and conditioning human body, adopt the method for vital base and primordial QI consolidating, spleen invigorating YIN nourishing, kidney-replenishing blood-nourishing, pathogenic fire purging diuresis, heat-clearing and toxic substances removing, blood circulation promoting and blood stasis dispelling, tonifying Qi and lifting yang.
The present invention provides a kind of Chinese medicinal tablet promoting bladder cancer post-operative recovery from the viewpoint of strengthening autoimmunity two for single disease and comprehensive conditioning human body to achieve these goals, this Chinese medicinal tablet adopts the method for vital base and primordial QI consolidating, spleen invigorating YIN nourishing, kidney-replenishing blood-nourishing, eliminating fire and detoxication, clearing away heat and promoting diuresis, blood circulation promoting and blood stasis dispelling, tonifying Qi and lifting yang, can the effective complication that causes of prevention and therapy Intravesical BCG, and perfusion operates the urinary tract infection caused, improve patient's autoimmunity, reduce patient suffering, promote patient's post-operative recovery.
The invention provides a kind of Chinese medicinal tablet promoting bladder cancer post-operative recovery, processed by raw material of Chinese medicine medicine and medicine acceptable carrier and be prepared from, the crude drug composition of described Chinese medicinal tablet effective ingredient and parts by weight are: Radix Panacis Quinquefolii 8-15 part, Rhizoma Polygonati 5-10 part, Radix Angelicae Sinensis 10-15 part, Herba Leonuri 7-15 part, hippocampus 3-9 parts, Fructus Lycii 15-20 part, Radix Astragali 10-20 part, Carapax Eriocheir sinensis 3-8 part, Radix Glycyrrhizae Preparata 8-15 part, Caulis Akebiae 9-16 part, Herba Polygoni Avicularis 8-12 part, Cortex Phellodendri 6-12 part, Fructus Forsythiae 8-13 part, Radix Rehmanniae Preparata 7-15 part, Radix Rehmanniae 6-10 part, Radix Angelicae Dahuricae 6-12 part, Talcum 2-5 part, Radix Isatidis 15-25 part, Rhizoma Imperatae 3-8 part, Radix Scutellariae 6-10 part, Semen Pharbitidis 5-10 part.
Further, described Chinese medicinal tablet effective ingredient crude drug composition and parts by weight be: Radix Panacis Quinquefolii 8 parts, Rhizoma Polygonati 5 parts, Radix Angelicae Sinensis 10 parts, Herba Leonuri 7 parts, hippocampus 3 part, Fructus Lycii 15 parts, the Radix Astragali 10 parts, Carapax Eriocheir sinensis 3 parts, Radix Glycyrrhizae Preparata 8 parts, Caulis Akebiae 9 Fen ， Herba Polygoni Avicularis 8 parts, Cortex Phellodendri 6 parts, Fructus Forsythiae 8 parts, Radix Rehmanniae Preparata 7 parts, Radix Rehmanniae 6 parts, the Radix Angelicae Dahuricae 6 parts, 2 parts, Talcum, Radix Isatidis 15 parts, Rhizoma Imperatae 3 parts, Radix Scutellariae 6 parts, Semen Pharbitidis 5 parts.
Further, described Chinese medicinal tablet effective ingredient crude drug composition and parts by weight be: Radix Panacis Quinquefolii 15 parts, Rhizoma Polygonati 10 parts, Radix Angelicae Sinensis 15 parts, Herba Leonuri 15 parts, Hippocampus 9 parts, Fructus Lycii 20 parts, the Radix Astragali 20 parts, Carapax Eriocheir sinensis 8 parts, Radix Glycyrrhizae Preparata 15 parts, Caulis Akebiae 16 Fen ， Herba Polygoni Avicularis 12 parts, Cortex Phellodendri 12 parts, Fructus Forsythiae 13 parts, Radix Rehmanniae Preparata 15 parts, Radix Rehmanniae 10 parts, the Radix Angelicae Dahuricae 12 parts, 5 parts, Talcum, Radix Isatidis 25 parts, Rhizoma Imperatae 8 parts, Radix Scutellariae 10 parts, Semen Pharbitidis 10 parts.
Further, described Chinese medicinal tablet effective ingredient crude drug composition and parts by weight be: Radix Panacis Quinquefolii 13 parts, Rhizoma Polygonati 8 parts, Radix Angelicae Sinensis 12 parts, Herba Leonuri 10 parts, Hippocampus 6 parts, Fructus Lycii 17 parts, the Radix Astragali 15 parts, Carapax Eriocheir sinensis 6 parts, Radix Glycyrrhizae Preparata 12 parts, Caulis Akebiae 13 Fen ， Herba Polygoni Avicularis 10 parts, Cortex Phellodendri 9 parts, Fructus Forsythiae 10 parts, Radix Rehmanniae Preparata 12 parts, Radix Rehmanniae 8 parts, the Radix Angelicae Dahuricae 8 parts, 3 parts, Talcum, Radix Isatidis 20 parts, Rhizoma Imperatae 5 parts, Radix Scutellariae 8 parts, Semen Pharbitidis 7 parts.
Further, described medicine acceptable carrier comprises: binding agent, disintegrating agent, one or both in fluidizer, lubricant; Wherein, described binding agent can be starch, dextrin, maltodextrin, carboxymethyl cellulose, sucrose, alginic acid and alginate, xanthan gum; Wherein, described disintegrating agent can be crospolyvinylpyrrolidone, carboxymethyl starch and soybean polysaccharide; Wherein, described fluidizer can be micropowder silica gel, Pulvis Talci and hydrated sodium aluminosilicate; Wherein, described lubricant can be magnesium stearate, calcium stearate, Polyethylene Glycol, hydrogenated vegetable oil.
Present invention also offers the preparation method of the Chinese medicinal tablet of described promotion bladder cancer post-operative recovery, comprise the following steps:
Step 1: grind into powder after Carapax Eriocheir sinensis training Huang, obtain Carapax Eriocheir sinensis powder, Hippocampus grinds to obtain Hippocampus powder into powder;
Step 2: the Carapax Eriocheir sinensis powder obtained in step 1 and Hippocampus powder and other crude drug are added the water that weight multiple is 9 times, decocts twice, decocts 30-60 minute at every turn, filters after decocting; Merge the filtrate of twice, being concentrated into relative density is 1.00 ~ 1.10 (60 DEG C), obtain concentrated solution, adding ethanol makes the mass fraction of ethanol reach 65%, stir evenly, leave standstill 24 ~ 48 hours, filter and reclaim ethanol, being concentrated into the thick paste that relative density is 1.15 ~ 1.25 (60 DEG C);
Step 3: add described medicine acceptable carrier in the thick paste that step 2 is obtained, mixing, granulate, dry, tabletting and get final product.
The present invention is in order to the complication of the Intravesical BCG treatment after prevention and therapy underwent transurethral resection of bladder tumor, promote bladder cancer patients post-operative recovery, alleviate patient suffering, adopt the method for vital base and primordial QI consolidating, spleen invigorating YIN nourishing, kidney-replenishing blood-nourishing, pathogenic fire purging diuresis, heat-clearing and toxic substances removing, blood circulation promoting and blood stasis dispelling, tonifying Qi and lifting yang, while carrying out treating for single disease, comprehensive conditioning human body strengthens autoimmunity.According to Chinese medical theory determination for the treatment of based on pathogenesis obtained through differentiation of symptoms and signs, screen raw material of Chinese medicine by great many of experiments, refining agent method, make each efficacy of drugs produce synergism, thus reach the effect for the treatment of both the principal and secondary aspects of a disease.In the crude drug chosen, Radix Panacis Quinquefolii boosting qi and nourishing yin, clearing away heat and promoting production of body fluid, lose for deficiency of vital energy the moon, deficiency-heat is tired of tired, quenches one's thirst, resisting fatigue; Rhizoma Polygonati nourishing kidney profit spleen, invigorating the spleen and replenishing QI, has effect of kidney tonifying, spleen invigorating, yin nourishing, lung moistening, can be used for treating weakness of the spleen and stomach, asthenia of essence and blood, and body void is weak; Chinese angelica blood supplementing is invigorated blood circulation, menstruction regulating and pain relieving, loosening bowel to relieve constipation; Herba Leonuri promoting blood flow to regulate menstruation, promoting the circulation of blood dissipating blood stasis, diuresis, cures mainly menoxenia, puerperal abdominal pain due to blood stasis, edema, dysuria; Hippocampus warming the kidney to invigorate YANG, mass dissipating and swelling eliminating, for sexual impotence, the enuresis, suffers from a deficiency of the kidney and breathes heavily, lump in the abdomen, injury from falling down; Fructus Lycii nourishing the liver and kidney, replenishing vital essence to improve eyesight, for asthenia damage of essence, soreness of waist and knee joint, vertigo and tinnitus, impotence and seminal emission, interior-heat is quenched one's thirst, blood deficiency and yellow complexion, and blurred vision is failed to understand; The Radix Astragali is warm in nature, sweet in the mouth, tonifying Qi and lifting yang, and benefit defends consolidating superficial resistance, promoting pus discharge and tissue regeneration strengthening, diuretic detumescent, cures mainly weakness of the spleen and stomach, lack of appetite; Carapax Eriocheir sinensis removing blood stasis with potent drugs removing food stagnancy, controls blood stasis and stagnates, hypochondriac pain, stomachache, acute mastitis, chilblain, and its chitin contained can absorb oil in vivo rapidly, and excretes, and has blood fat reducing, blood pressure lowering, improves diabetes, antitumor, improves the effects such as constipation; The sweet temperature of Radix Glycyrrhizae Preparata, returns spleen, stomach, lung meridian, has QI invigorating tonify deficiency, preventing phlegm from forming and stopping coughing, relieving spasm to stop pain, and the raw sun of tonifying YIN, in the high violent prescription of the property of medicine, can relax strong or alleviate toxic and side effects, again can the spleen and stomach regulating; Caulis Akebiae has effect of pathogenic fire purging row water, promoting blood circulation, stimulating milk secretion of stimulating the menstrual flow, cures mainly damp-heat in the urinary bladder, oliguria with reddish urine burning pain, aphtha, vexed insomnia etc.; Effect that Cortex Phellodendri has heat clearing and damp drying, pathogenic fire purging removes steaming, detoxification sore treatment; Herba Polygoni Avicularis has effect that hardship falls row, tonneau bladder, bitter dry, parasite killing removing damp to relieve itching, cures mainly dysuria, Urethra astringent pain, eczema; Fructus Forsythiae has effect of heat-clearing and toxic substances removing, mass dissipating and swelling eliminating, and Fructus Forsythiae concentrated decotion has antibacterial action in vitro, can suppress Bacillus typhi, Salmonella paratyphi, escherichia coli, dysentery bacterium, diphtheria corynebacterium and vibrio cholera, staphylococcus, streptococcus etc.; Radix Rehmanniae Preparata nourishing YIN and supplementing blood, beneficial essence fills out marrow, and the Dihuang polysaccharide contained by Radix Rehmanniae Preparata has obvious immune tumor activity, also there is heart tonifying, diuresis, protect the liver, blood sugar lowering, anti-proliferate, exudation, antiinflammatory, antifungal, the effect such as anti-radiation; Radix Angelicae Dahuricae expelling wind and cold, understand things pain-stopping, detumescence and apocenosis, dampness leukorrhagia stopping, sharp blood vessels, expelling wind and cold, eliminating dampness and dredging channels, the Radix Angelicae Dahuricae all has inhibitory action to escherichia coli, dysentery bacterium, Bacillus proteus, Bacillus typhi, Salmonella paratyphi, bacillus pyocyaneus, vibrio cholera, Bacillus tuberculosis etc.; Talcum has effect of inducing diuresis for treating stranguria syndrome, clearing away summer-heat, damp eliminating sore; Radix Rehmanniae has effect of clearing away heat and cooling blood, YIN nourishing and the production of body fluid promoting, pain relieving regulating menstruation, cures mainly heat and enters nutrient blood, fever of the body xerostomia, urinary tract infection; Rhizoma Imperatae cooling blood for hemostasis, clearing away heat and promoting diuresis, cures mainly haematemesis, hematuria, pyretic stranguria, edema, dysuria etc.; Radix Isatidis heat-clearing and toxic substances removing, removing heat from blood, cures mainly cold, fever, macule, erysipelas, sore and toxic; Radix Scutellariae heat clearing and damp drying, eliminating fire and detoxication, hemostasis, antiabortive, cure mainly damp and hot caused jaundice, dysentery, pyretic stranguria, carbuncle sore tumefacting virus, high fever excessive thirst, cough due to lung-heat, high hot excessive thirst; Semen Pharbitidis removing water retention by purgation, drink is washed in expectorant, and parasite killing is attacked long-pending, cures mainly the difficulty in urination and defecation of edema distension, phlegm retention cough with asthma, abdominal pain due to worm stagnation.
Radix Panacis Quinquefolii in these crude drug, Rhizoma Polygonati, Radix Angelicae Sinensis, Herba Leonuri, Hippocampus, Fructus Lycii, the Radix Astragali, Radix Rehmanniae synergism has spleen invigorating YIN nourishing, kidney-replenishing blood-nourishing, blood circulation promoting and blood stasis dispelling, effect of the raw sun of QI invigorating, wherein, Hippocampus and Fructus Lycii mutually 5 can its kidney invigorating effects of gain, Semen Pharbitidis and Hippocampus mutually 5 can the merits of gain promoting QI to circulate and dispersing the agglomeration of the pathogens, these medical materials can regulate body on the whole, strengthen patient's autoimmunity, alleviate the night sweat due to weak body physique symptom of patient, promote Rehabilitation, prevent patient from infecting upper activated tubercule bacillus in bacillus calmette-guerin vaccine because of nourishing kidney-yin, the side reaction of prevention whole body, Herba Leonuri, Caulis Akebiae, Herba Polygoni Avicularis, Talcum, Rhizoma Imperatae, Semen Pharbitidis all possess the effect of pathogenic fire purging diuresis, can effectively prevention and therapy local side reaction in frequent micturition, urgent micturition, dysurea, hematuria symptom, Herba Polygoni Avicularis, Cortex Phellodendri, Fructus Forsythiae, Radix Rehmanniae Preparata, the Radix Angelicae Dahuricae, the Radix Rehmanniae, Radix Isatidis all have antibiotic effect, effectively can pour into the urinary tract infection caused by operation by prevention and therapy, Caulis Akebiae, Cortex Phellodendri, Fructus Forsythiae, Radix Rehmanniae, Radix Isatidis, Rhizoma Imperatae, Radix Scutellariae all have effect of heat-clearing and toxic substances removing, can treat and prevent the heating paresthesia of complication or the urinary tract infection initiation caused by Intravesical BCG, Radix Rehmanniae Preparata and Carapax Eriocheir sinensis also have antineoplastic action, can suppress cancer return, Radix Glycyrrhizae Preparata can play and middle QI invigorating wherein, the mediation property of medicine, relieving spasm to stop pain effect.All medicines share above, can urinary tract infection caused by the treatment of prevention and therapy irrigation of bladder for postoperative bladder cancer patients and the complication that causes of Intravesical BCG, vital base and primordial QI consolidating, improve patient's autoimmunity, promote post-operative recovery, and all medicines are nursed one's health mutually, little to body harmful effect, clinical practice is more safe and effective.
Beneficial effect of the present invention is: the invention provides a kind of Chinese medicinal tablet promoting bladder cancer post-operative recovery.This Chinese medicinal tablet promotes patient postoperative rehabilitation by the complication of bladder instillation to treat after prevention and therapy operation in patients with raising patient autoimmunity.Adopt the method for vital base and primordial QI consolidating, spleen invigorating YIN nourishing, kidney-replenishing blood-nourishing, eliminating fire and detoxication, clearing away heat and promoting diuresis, blood circulation promoting and blood stasis dispelling, tonifying Qi and lifting yang, can the effective complication that causes of prevention and therapy Intravesical BCG, and perfusion operates the urinary tract infection caused, improve patient's autoimmunity, reduce patient suffering, promote patient's post-operative recovery.Meanwhile, the effect of certain suppression cancer return also can be played in this tablet containing antineoplastic composition.
Detailed description of the invention
According to following embodiment, the present invention may be better understood.But those skilled in the art will readily understand, concrete material proportion, process conditions and result thereof described by embodiment only should can not limit the present invention described in detail in claims yet for illustration of the present invention.
Embodiment 1 prepares the Chinese medicinal tablet promoting bladder cancer post-operative recovery
Formula:
Crude drug: Radix Panacis Quinquefolii 8 grams, Rhizoma Polygonati 5 grams, Radix Angelicae Sinensis 10 grams, Herba Leonuri 7 grams, hippocampus 3 gram, Fructus Lycii 15 grams, the Radix Astragali 10 grams, Carapax Eriocheir sinensis 3 grams, Radix Glycyrrhizae Preparata 8 grams, Caulis Akebiae 9 Ke ， Herba Polygoni Avicularis 8 grams, Cortex Phellodendri 6 grams, Fructus Forsythiae 8 grams, Radix Rehmanniae Preparata 7 grams, Radix Rehmanniae 6 grams, the Radix Angelicae Dahuricae 6 grams, 2 grams, Talcum, Radix Isatidis 15 grams, Rhizoma Imperatae 3 grams, Radix Scutellariae 6 grams, Semen Pharbitidis 5 grams.
Adjuvant: carboxymethyl cellulose (binding agent) 6 grams,
Crospolyvinylpyrrolidone (disintegrating agent) 6 grams,
Micropowder silica gel (fluidizer) 1 gram,
Magnesium stearate (lubricant) 1 gram
Compound method is:
Step 1: grind into powder after Carapax Eriocheir sinensis training Huang, obtain Carapax Eriocheir sinensis powder, Hippocampus grinds to obtain Hippocampus powder into powder;
Step 2: the Carapax Eriocheir sinensis powder obtained in step 1 and Hippocampus powder and other crude drug are added the water that weight multiple is 9 times, decocts twice, decocts 45 minutes at every turn, filters after decocting; Merge the filtrate of twice, being concentrated into relative density is 1.00 ~ 1.10 (60 DEG C), obtains concentrated solution, adding ethanol makes the mass fraction of ethanol reach 65%, stirs evenly, and leaves standstill 36 hours, filter and reclaim ethanol, being concentrated into the thick paste that relative density is 1.15 ~ 1.25 (60 DEG C);
Step 3: add adjuvant in the thick paste that step 2 is obtained, mixing, granulate, dry, tabletting and get final product.
Using method: for prevention, one time 3,3 times on the one; Be used for the treatment of, one time 5,3 times on the one 10th is a course for the treatment of.
Embodiment 2 prepares the Chinese medicinal tablet promoting bladder cancer post-operative recovery
Formula:
Crude drug: Radix Panacis Quinquefolii 15 grams, Rhizoma Polygonati 10 grams, Radix Angelicae Sinensis 15 grams, Herba Leonuri 15 grams, Hippocampus 9 grams, Fructus Lycii 20 grams, the Radix Astragali 20 grams, Carapax Eriocheir sinensis 8 grams, Radix Glycyrrhizae Preparata 15 grams, Caulis Akebiae 16 Ke ， Herba Polygoni Avicularis 12 grams, Cortex Phellodendri 12 grams, Fructus Forsythiae 13 grams, Radix Rehmanniae Preparata 15 grams, Radix Rehmanniae 10 grams, the Radix Angelicae Dahuricae 12 grams, 5 grams, Talcum, Radix Isatidis 25 grams, Rhizoma Imperatae 8 grams, Radix Scutellariae 10 grams, Semen Pharbitidis 10 grams.
Adjuvant: maltodextrin (binding agent) 6 grams,
Carboxymethyl starch (disintegrating agent) 6 grams,
Pulvis Talci (fluidizer) 1 gram,
Calcium stearate (lubricant) 1 gram
Compound method is:
Step 1: grind into powder after Carapax Eriocheir sinensis training Huang, obtain Carapax Eriocheir sinensis powder, Hippocampus grinds to obtain Hippocampus powder into powder;
Step 2: the Carapax Eriocheir sinensis powder obtained in step 1 and Hippocampus powder and other crude drug are added the water that weight multiple is 9 times, decocts twice, decocts 30 minutes at every turn, filters after decocting; Merge the filtrate of twice, being concentrated into relative density is 1.00 ~ 1.10 (60 DEG C), obtains concentrated solution, adding ethanol makes the mass fraction of ethanol reach 65%, stirs evenly, and leaves standstill 48 hours, filter and reclaim ethanol, being concentrated into the thick paste that relative density is 1.15 ~ 1.25 (60 DEG C);
Step 3: add adjuvant in the thick paste that step 2 is obtained, mixing, granulate, dry, tabletting and get final product.
Using method: for prevention, one time 3,3 times on the one; Be used for the treatment of, one time 5,3 times on the one 10th is a course for the treatment of.
Embodiment 3 prepares the Chinese medicinal tablet promoting bladder cancer post-operative recovery
Formula:
Crude drug: Radix Panacis Quinquefolii 13 grams, Rhizoma Polygonati 8 grams, Radix Angelicae Sinensis 12 grams, Herba Leonuri 10 grams, Hippocampus 6 grams, Fructus Lycii 17 grams, the Radix Astragali 15 grams, Carapax Eriocheir sinensis 6 grams, Radix Glycyrrhizae Preparata 12 grams, Caulis Akebiae 13 Ke ， Herba Polygoni Avicularis 10 grams, Cortex Phellodendri 9 grams, Fructus Forsythiae 10 grams, Radix Rehmanniae Preparata 12 grams, Radix Rehmanniae 8 grams, the Radix Angelicae Dahuricae 8 grams, 3 grams, Talcum, Radix Isatidis 20 grams, Rhizoma Imperatae 5 grams, Radix Scutellariae 8 grams, Semen Pharbitidis 7 grams.
Adjuvant: starch (binding agent) 6 grams,
Soybean polysaccharide (disintegrating agent) 6 grams,
Hydrated sodium aluminosilicate (fluidizer) 1 gram,
Polyethylene Glycol (lubricant) 1 gram
Compound method is:
Step 1: grind into powder after Carapax Eriocheir sinensis training Huang, obtain Carapax Eriocheir sinensis powder, Hippocampus grinds to obtain Hippocampus powder into powder;
Step 2: the Carapax Eriocheir sinensis powder obtained in step 1 and Hippocampus powder and other crude drug are added the water that weight multiple is 9 times, decocts twice, decocts 60 minutes at every turn, filters after decocting; Merge the filtrate of twice, being concentrated into relative density is 1.00 ~ 1.10 (60 DEG C), obtains concentrated solution, adding ethanol makes the mass fraction of ethanol reach 65%, stirs evenly, and leaves standstill 24 hours, filter and reclaim ethanol, being concentrated into the thick paste that relative density is 1.15 ~ 1.25 (60 DEG C);
Step 3: add adjuvant in the thick paste that step 2 is obtained, mixing, granulate, dry, tabletting and get final product.
Using method: for prevention, one time 3,3 times on the one; Be used for the treatment of, one time 5,3 times on the one 10th is a course for the treatment of.
Embodiment 4 clinical experimental study
Give the Chinese medicinal tablet of any one of the embodiment of the present invention 1 to 3, using method is: the complication caused for prevention of postoperative irrigation of bladder, one time 3,3 times on the one, each perfusion starts administration from the last week, discontinues medication to pouring into latter one month; Be used for the treatment of irrigation of bladder cause complication, one time 5,3 times on the one 10th is a course for the treatment of, symptom eliminate after continue to consolidate medication one month.
Experiment of preventive effects:
Random selecting 300, in age 30-60 year, average 45 years old, the non-Myometrial involvement bladder tumor patients of underwent transurethral resection of bladder tumor need be done, at every turn start administration the last week from irrigation of bladder bacillus calmette-guerin vaccine, discontinuing medication to pouring into latter one month, adhering to use 2 years, period, there is the complication that urinary tract infection and other Intravesical BCGs cause in none routine patient, cystoscope check once in postoperative every 3 months, in order, nothing recurs sign to patient's post-operative recovery.
Therapeutic effect is tested:
Random selecting 100 patients led to complications by intravesical BCG therapy, age 40-60 year, average 50 years old, carry out intravesical BCG therapy and treat more than 3 times, there is the symptom of this cystitis of class, urine urgency-frequency dysurea, wherein, 15 patients have hematuria symptom, 18 patient's urinary tract infection, 35 patients have the symptom of night sweat due to weak body physique, 10 patients have lasting low grade fever symptom, 5 people have fervescence, 13 people have inappetence symptom, 10 people have headache syndromes, 12 people have nausea and vomiting symptom, 25 patients have the symptom of muscular soreness for a long time, there is Tuberculous septicemia symptom in 1 people.After taking 3 courses for the treatment of of Tablets, 25 people's complication symptoms are eliminated completely, and 69 people's symptoms are clearly better, and it is invalid that 6 people use.
Clinical exemplary embodiments:
1, Chen, 35 years old, man, after underwent transurethral resection of bladder tumor, carries out intravesical BCG therapy and treats 8 times, there is frequent micturition, urgent micturition, dysurea, be diagnosed as chronic cystitis, after taking 3 courses for the treatment of of Tablets, frequent micturition, urgent micturition, dysurea are eliminated, symptom continues to take Tablets 1 month after eliminating, chronic cystitis rehabilitation.
2, Lee, 50 years old, female, after underwent transurethral resection of bladder tumor, carry out intravesical BCG therapy and treat 8 times, occur frequent micturition, urgent micturition, dysurea, hematuria and lasting low grade fever symptom, after taking 3 courses for the treatment of of Tablets, dysurea, hematuria and lasting low grade fever symptom are eliminated, and frequent micturition, symptoms of urgency are clearly better.
3, together certain, 58 years old, man, after underwent transurethral resection of bladder tumor, carries out intravesical BCG therapy and treats 10 times, there is frequent micturition, urgent micturition, dysurea, hematuria, high fever, headache, vomiting, inappetence, be diagnosed as cystitis and urinary tract infection, after taking 3 courses for the treatment of of Tablets, hematuria, high heat, headache, vomiting, inappetence symptom are eliminated, frequent micturition, symptoms of urgency take a turn for the better to some extent, urinary tract infection rehabilitation.
Claims (6)
1. one kind promotes the Chinese medicinal tablet of bladder cancer post-operative recovery, processed by raw material of Chinese medicine medicine and medicine acceptable carrier and be prepared from, it is characterized in that, the crude drug composition of described Chinese medicinal tablet effective ingredient and parts by weight are: Radix Panacis Quinquefolii 8-15 part, Rhizoma Polygonati 5-10 part, Radix Angelicae Sinensis 10-15 part, Herba Leonuri 7-15 part, hippocampus 3-9 parts, Fructus Lycii 15-20 part, Radix Astragali 10-20 part, Carapax Eriocheir sinensis 3-8 part, Radix Glycyrrhizae Preparata 8-15 part, Caulis Akebiae 9-16 part, Herba Polygoni Avicularis 8-12 part, Cortex Phellodendri 6-12 part, Fructus Forsythiae 8-13 part, Radix Rehmanniae Preparata 7-15 part, Radix Rehmanniae 6-10 part, Radix Angelicae Dahuricae 6-12 part, Talcum 2-5 part, Radix Isatidis 15-25 part, Rhizoma Imperatae 3-8 part, Radix Scutellariae 6-10 part, Semen Pharbitidis 5-10 part.
2. the Chinese medicinal tablet promoting bladder cancer post-operative recovery as claimed in claim 1, is characterized in that, the crude drug composition of described Chinese medicinal tablet effective ingredient and parts by weight are: Radix Panacis Quinquefolii 8 parts, Rhizoma Polygonati 5 parts, Radix Angelicae Sinensis 10 parts, Herba Leonuri 7 parts, hippocampus 3 part, Fructus Lycii 15 parts, the Radix Astragali 10 parts, Carapax Eriocheir sinensis 3 parts, Radix Glycyrrhizae Preparata 8 parts, Caulis Akebiae 9 parts of Herba Polygoni Avicularis 8 parts, Cortex Phellodendri 6 parts, Fructus Forsythiae 8 parts, Radix Rehmanniae Preparata 7 parts, Radix Rehmanniae 6 parts, the Radix Angelicae Dahuricae 6 parts, 2 parts, Talcum, Radix Isatidis 15 parts, Rhizoma Imperatae 3 parts, Radix Scutellariae 6 parts, Semen Pharbitidis 5 parts.
3. the Chinese medicinal tablet promoting bladder cancer post-operative recovery as claimed in claim 1, is characterized in that, the crude drug composition of described Chinese medicinal tablet effective ingredient and parts by weight are: Radix Panacis Quinquefolii 15 parts, Rhizoma Polygonati 10 parts, Radix Angelicae Sinensis 15 parts, Herba Leonuri 15 parts, Hippocampus 9 parts, Fructus Lycii 20 parts, the Radix Astragali 20 parts, Carapax Eriocheir sinensis 8 parts, Radix Glycyrrhizae Preparata 15 parts, Caulis Akebiae 16 Fen ， Herba Polygoni Avicularis 12 parts, Cortex Phellodendri 12 parts, Fructus Forsythiae 13 parts, Radix Rehmanniae Preparata 15 parts, Radix Rehmanniae 10 parts, the Radix Angelicae Dahuricae 12 parts, 5 parts, Talcum, Radix Isatidis 25 parts, Rhizoma Imperatae 8 parts, Radix Scutellariae 10 parts, Semen Pharbitidis 10 parts.
4. the Chinese medicinal tablet promoting bladder cancer post-operative recovery as claimed in claim 1, is characterized in that, the crude drug composition of described Chinese medicinal tablet effective ingredient and parts by weight are: Radix Panacis Quinquefolii 13 parts, Rhizoma Polygonati 8 parts, Radix Angelicae Sinensis 12 parts, Herba Leonuri 10 parts, Hippocampus 6 parts, Fructus Lycii 17 parts, the Radix Astragali 15 parts, Carapax Eriocheir sinensis 6 parts, Radix Glycyrrhizae Preparata 12 parts, Caulis Akebiae 13 Fen ， Herba Polygoni Avicularis 10 parts, Cortex Phellodendri 9 parts, Fructus Forsythiae 10 parts, Radix Rehmanniae Preparata 12 parts, Radix Rehmanniae 8 parts, the Radix Angelicae Dahuricae 8 parts, 3 parts, Talcum, Radix Isatidis 20 parts, Rhizoma Imperatae 5 parts, Radix Scutellariae 8 parts, Semen Pharbitidis 7 parts.
5. the Chinese medicinal tablet of the promotion bladder cancer post-operative recovery according to any one of Claims 1-4, is characterized in that, described medicine acceptable carrier comprises: binding agent, disintegrating agent, one or both in fluidizer, lubricant; Wherein, described binding agent can be starch, dextrin, maltodextrin, carboxymethyl cellulose, sucrose, alginic acid and alginate, xanthan gum; Wherein, described disintegrating agent can be crospolyvinylpyrrolidone, carboxymethyl starch and soybean polysaccharide; Wherein, described fluidizer can be micropowder silica gel, Pulvis Talci and hydrated sodium aluminosilicate; Wherein, described lubricant can be magnesium stearate, calcium stearate, Polyethylene Glycol, hydrogenated vegetable oil.
6. the preparation method promoting the Chinese medicinal tablet of bladder cancer post-operative recovery as claimed in claim 1, is characterized in that, comprise the following steps:
Step 1: grind into powder after Carapax Eriocheir sinensis training Huang, obtain Carapax Eriocheir sinensis powder, Hippocampus grinds to obtain Hippocampus powder into powder;
Step 2: the Carapax Eriocheir sinensis powder obtained in step 1 and Hippocampus powder and other crude drug are added the water that weight multiple is 9 times, decocts twice, decocts 30-60 minute at every turn, filters after decocting; Merge the filtrate of twice, being concentrated into relative density is 1.00 ~ 1.10 (60 DEG C), obtain concentrated solution, adding ethanol makes the mass fraction of ethanol reach 65%, stir evenly, leave standstill 24 ~ 48 hours, filter and reclaim ethanol, being concentrated into the thick paste that relative density is 1.15 ~ 1.25 (60 DEG C);
Step 3: add described medicine acceptable carrier in the thick paste that step 2 is obtained, mixing, granulate, dry, tabletting and get final product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410788961.3A CN104524275B (en) | 2014-12-17 | 2014-12-17 | A kind of Chinese medicinal tablet for promoting carcinoma of urinary bladder post-operative recovery and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410788961.3A CN104524275B (en) | 2014-12-17 | 2014-12-17 | A kind of Chinese medicinal tablet for promoting carcinoma of urinary bladder post-operative recovery and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104524275A true CN104524275A (en) | 2015-04-22 |
| CN104524275B CN104524275B (en) | 2018-04-03 |
Family
ID=52840031
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410788961.3A Expired - Fee Related CN104524275B (en) | 2014-12-17 | 2014-12-17 | A kind of Chinese medicinal tablet for promoting carcinoma of urinary bladder post-operative recovery and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104524275B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105412490A (en) * | 2016-01-09 | 2016-03-23 | 青岛辰达生物科技有限公司 | Medicine preparation for treating superficial bladder cancer and application thereof |
| CN114984158A (en) * | 2022-07-21 | 2022-09-02 | 上海中医药大学附属龙华医院 | Traditional Chinese medicine composition for treating non-muscle invasive bladder cancer |
| US11793851B2 (en) * | 2020-09-03 | 2023-10-24 | Chen-Yu Lee | Method for treating a side effect caused by BCG perfusion therapy for bladder cancer |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1421238A (en) * | 2002-12-23 | 2003-06-04 | 丁铁岭 | Natural bioreaction regulator with the functions of resisting cancer, resisting free radical damage and regulating immunity |
| CN102727805A (en) * | 2011-04-03 | 2012-10-17 | 王维德 | Cancer treating medicine |
| CN104000946A (en) * | 2014-06-18 | 2014-08-27 | 张财 | Externally-applied traditional Chinese medicine for treating carcinoma of urinary bladder |
-
2014
- 2014-12-17 CN CN201410788961.3A patent/CN104524275B/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1421238A (en) * | 2002-12-23 | 2003-06-04 | 丁铁岭 | Natural bioreaction regulator with the functions of resisting cancer, resisting free radical damage and regulating immunity |
| CN102727805A (en) * | 2011-04-03 | 2012-10-17 | 王维德 | Cancer treating medicine |
| CN104000946A (en) * | 2014-06-18 | 2014-08-27 | 张财 | Externally-applied traditional Chinese medicine for treating carcinoma of urinary bladder |
Non-Patent Citations (2)
| Title |
|---|
| 张洪亮 等: "膀胱癌", 《新疆中医药》 * |
| 陈惠 等: "近年来中西结合治疗膀胱癌的研究进展", 《中华中医药学刊》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105412490A (en) * | 2016-01-09 | 2016-03-23 | 青岛辰达生物科技有限公司 | Medicine preparation for treating superficial bladder cancer and application thereof |
| US11793851B2 (en) * | 2020-09-03 | 2023-10-24 | Chen-Yu Lee | Method for treating a side effect caused by BCG perfusion therapy for bladder cancer |
| CN114984158A (en) * | 2022-07-21 | 2022-09-02 | 上海中医药大学附属龙华医院 | Traditional Chinese medicine composition for treating non-muscle invasive bladder cancer |
| CN114984158B (en) * | 2022-07-21 | 2023-06-20 | 上海中医药大学附属龙华医院 | Traditional Chinese medicine composition for preventing postoperative recurrence of non-myogenic invasive bladder cancer, and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104524275B (en) | 2018-04-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102920820A (en) | Traditional Chinese medicine composition for treating chronic colitis | |
| CN104288701A (en) | Traditional Chinese medicine composition for treating cholecystitis | |
| CN103041033A (en) | Traditional Chinese medicine composition for treating renal calculus | |
| CN104524275A (en) | Chinese medicinal tablet for promoting recovery of patients from operation for bladder cancer preparation method thereof | |
| CN102671070A (en) | Traditional Chinese medicine composition for treating cancers or tumors | |
| CN104043089A (en) | Medical biological dressing suppository for treating hemorrhoid | |
| CN102961653A (en) | Medicine compound for treating gonorrhoea, urethritis and prostatitis | |
| CN103908616B (en) | The medicament of tumor remission patient radiotherapy side effect and preparation method | |
| CN102935214B (en) | Traditional Chinese medicinal composition for treating uremia | |
| CN105521332A (en) | Traditional Chinese medicinal composition for treating anal fissure, and preparation method and application thereof | |
| CN105233208A (en) | Traditional Chinese medicine preparation for treating heart failure | |
| CN105250758A (en) | Traditional Chinese medicine composition for treating diabetes | |
| CN104888178A (en) | Infantile diarrhea treatment traditional Chinese medicine | |
| CN104274553A (en) | Traditional Chinese medicine with effect of relaxing bowels | |
| CN104547549A (en) | Traditional Chinese medicine composition for preventing and controlling radiodermatitis | |
| CN103721028B (en) | One treats anginal medicine and preparation method | |
| CN103285116B (en) | Traditional Chinese medicine preparation for treating influenza of infant | |
| CN105853882A (en) | Medicine for treating stomach illness and preparation method | |
| CN104984031A (en) | Traditional Chinese medicine preparation for treating eczema and dermatitis | |
| CN105055653A (en) | Medicine decoction for treating pulpitis and preparation method thereof | |
| CN105457004A (en) | Orally-taken medicine for treating stomachaches caused by deficient cold of spleens and stomachs and preparation method thereof | |
| CN105079487A (en) | Traditional Chinese medicine composition for treating heat stranguria | |
| CN105327299A (en) | Medicine for treating idiopathic thrombocytopenic purpura | |
| CN105169111A (en) | Traditional Chinese medicine composition for treating chronic urticaria and application of traditional Chinese medicine composition | |
| CN104225009A (en) | Traditional Chinese medicine composition for treating diarrhea |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20180403 Termination date: 20181217 |